Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

NCT00217672 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: Docetaxel

Sponsor

Translational Oncology Research International

Collaborators

[object Object]